Navigation Links
LeMaitre Vascular Announces Changes to Its Executive Management Team

BURLINGTON, Mass., April 10 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the departure of Kevin D. Kelly, Senior Vice President, North American Sales, to pursue other business opportunities and the appointment of Robert V. Linden to Vice President, North American Sales.

Mr. Linden has approximately six years North American sales experience with LeMaitre Vascular. He joined LeMaitre Vascular in July 2002 as a Sales Representative and has served in positions of increasing responsibility within the North American organization. Since January 2008, he has served as Director of Sales for the Eastern United States and Canada, supervising three of the company's five North American sales regions. From 2005 through 2007, Mr. Linden served as Regional Sales Manager. Prior to LeMaitre Vascular, Mr. Linden served as a sales representative at several medical device companies, including Vasca, Inc., Atrium Medical Corporation, Active Medical, Inc., and DePuy Orthopedics, Inc. Mr. Linden holds a B.A. in Marketing from The Pennsylvania State University.

LeMaitre Vascular Chairman and Chief Executive Officer George W. LeMaitre stated, "We want to thank Kevin Kelly for his contributions and we wish him the best. We are thrilled to promote Rob Linden to the position of Vice President, North American Sales. I have watched Rob succeed at our company in positions of increasing responsibility over the past six years. We believe he will build on this experience to provide effective leadership for our North American sales organization."

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
5. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
6. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
7. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
8. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
9. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
10. Pot bellies linked to early signs of cardiovascular disease
11. Air pollution linked to cardiovascular risk indices in healthy young adults
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: